MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia

Get in while you can. Business is breakeven on its own without this result and current price essentially gives this result for free. IMO, a double or triple from here but go ahead and ask your AI friend of choice what they think.

Results on this trial are better than one approved by the FDA in 2023. There is something here for those willing to take a bit of risk,